Telomerase Inhibitors Pipeline Investigated in New DelveInsight Report Now Available at

21 May 2015 • by Natalie Aster

LONDON - Currently, the aim of drug design strategies as well as cancer therapies is to target cancer cells. However, there are a number of challenges associated with such therapies. A challenge related to differentiating between cancer cells and normal cells is the primary one.  An enzyme telomerase activity is amongst such differences. The latter one has turned into a drug target since it takes place in most of human cancers, but not in normal human cells.

A number of developments in the space have been made lately by KAEL-Gemvax and Geron.  This market represents a big opportunity for pharma market players resulting in new developments in the years to come.

New market research report “Telomerase Inhibitors - Pipeline Insights, 2015” worked out by DelveInsight offers a comprehensive discussion of the pipeline assets across the telomerase inhibitors. The study insightfully analyses the telomerase inhibitors landscape. It contains detailed drug profiles including descriptions of drugs, information on developments partners, MOA, etc. The report scrutinises the pipeline and covers products on different stages of development. The research study focuses on key market players and assists in identifying emerging ones.

Report Details:

Telomerase Inhibitors - Pipeline Insights, 2015
Published: May, 2015
Price: US$ 1,250.00

More cutting-edge research studies by the publisher are available at DelveInsight page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970